Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix

Basic Research in Cardiology

Volumn 110, Issue 2, 2015, Pages

  Robinson, Emma ^a   Cassidy, Roslyn S ^a   Tate, Mitchel ^a   Zhao, Youyou ^a   Lockhart, Samuel ^a   Calderwood, Danielle ^a   Church, Rachel ^a   McGahon, Mary K ^a   Brazil, Derek P ^a   McDermott, Barbara J ^a   Green, Brian D ^a   Grieve, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cardiac remodelling; Extracellular matrix; Glucagon like peptide 1; Inflammation; Myocardial infarction

Indexed keywords

EXENDIN 4; FIBRONECTIN; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HEART DISEASE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART PROTECTION; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FEMALE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFLAMMATION; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; PEPTIDES; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENOMS; VENTRICULAR REMODELING;

EID: 84935009269     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-015-0476-7     Document Type: Article

References (62)

1. Bell DS (2008) Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 14:924–932. doi:10.4158/EP.14.7.924
2. Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB (2011) Implications of new hypertension guidelines in the United States. Hypertension 58:361–366. doi:10.1161/HYPERTENSIONAHA.111.175463
3. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. doi:10.1016/S0140-6736(14)60107-0
4. Braunwald E (2013) Heart Failure. JACC. Heart Fail 1:1–20. doi:10.1016/j.jchf.2012.10.002
5. Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM (2013) National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998–2010. Circulation 128:2577–2584. doi:10.1161/CIRCULATIONAHA.113.003668
6. Grieve DJ, Cassidy RS, Green BD (2009) Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157:1340–1351. doi:10.1111/j.1476-5381.2009.00376.x
7. Tate M, Chong A, Robinson E, Green BD, Grieve DJ (2015) Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 172:721–736. doi:10.1111/bph.12943
8. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350. doi:10.1161/CIRCULATIONAHA.107.739938
9. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS (2008) Grieve DJ (2008) GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478:136–142. doi:10.1016/j.abb.2008.08.001
10. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242–2252. doi:10.1210/en.2003-0007
11. Vila Petroff MG, Egan JM, Wang X, Sollott SJ (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89:445–452. doi:10.1161/hh1701.095716
12. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43–52. doi:10.1172/JCI15595
13. Goodwill A, Tune J, Noblet J, Conteh A, Sassoon D, Casalini E, Mather K (2014) Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol 109:426. doi:10.1007/s00395-014-0426-9
14. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955–961. doi:10.1161/01.CIR.0000139339.85840.DD
15. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983. doi:10.2337/db08-1193
16. Poornima I, Brown S, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP (2008) Chronic glucagon-like peptide-1 (GLP-1) infusion sustains LV systolic function and prolongs survival in the spontaneously hypertensive-heart failure prone rat. Circ Heart Fail 1:153–160. doi:10.1161/CIRCHEARTFAILURE.108.766402
17. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes 59:1063–1073. doi:10.2337/db09-0955
18. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694–699. doi:10.1016/j.cardfail.2006.08.211
19. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146–151. doi:10.2337/diabetes.54.1.146
20. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501–510. doi:10.1016/j.jacc.2008.10.033
21. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes D (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76. doi:10.1186/1475-2840-9-76
22. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965. doi:10.1161/01.CIR.0000120505.91348.58
23. DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin G, Zhuang S, Zhao TC (2014) Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab 307:E630–E643. doi:10.1152/ajpendo.00109.2014
24. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ (2014) Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 3:507–517. doi:10.1016/j.molmet.2014.04.009
25. Arnette D, Gibson TB, Lawrence MC, January B, Khoo S, McGlynn K, Vanderbilt CA, Cobb MH (2003) Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic β cells. J Biol Chem 278:32517–32525. doi:10.1074/jbc.M301174200
26. Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol 202:431–439. doi:10.1677/JOE-09-0132
27. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, Bernier M (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in chinese hamster ovary cells. Endocrinology 140:1132–1140. doi:10.1210/endo.140.3.6550
28. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS (2007) Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18:1227–1238. doi:10.1681/ASN.2006070778
29. Pugazhenthi U, Velmurugan K, Tran A, Mahaffey G, Pugazhenthi S (2010) Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 53:2357–2368. doi:10.1007/s00125-010-1849-y
30. Wu XM, Ou QY, Zhao W, Liu J, Zhang H (2014) The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway. Exp Clin Endocrinol Diabetes 122:608–614. doi:10.1055/s-0034-1384584
31. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, Shah AM (2008) Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51:319–325. doi:10.1161/HYPERTENSIONAHA.107.101980
32. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 318:914–921. doi:10.1124/jpet.105.097824
33. Jeong K, Kwon H, Min C, Pak Y (2009) Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyocytes. Exp Mol Med 41:226–235. doi:10.3858/emm.2009.41.4.025
34. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, Suzuki YJ (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63:368–377. doi:10.1124/mol.63.2.368
35. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R (2010) Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120:254–265. doi:10.1172/JCI40295
36. Zhang X, Goncalves R, Mosser DM (2008) The isolation and characterization of murine macrophages. Curr Protoc Immunol Chapter: Unit 14.1. doi:10.1002/0471142735.im1401s83
37. Flynn LA, Blissett AR, Calomeni EP, Agarwal G (2010) Inhibition of collagen fibrillogenesis by cells expressing soluble extracellular domains of DDR1 and DDR2. J Mol Biol 395:533–543. doi:10.1016/j.jmb.2009.10.073
38. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, Taffet GE, Entman ML (2010) Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 49:499–507. doi:10.1016/j.yjmcc.2010.05.005
39. Lal H, Ahmad F, Zhou J, Yu JE, Vagnozzi RJ, Guo Y, Yu D, Tsai EJ, Woodgett J, Gao E, Force T (2014) Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130:419–430. doi:10.1161/CIRCULATIONAHA.113.008364
40. Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153(Suppl 1):S137–S153. doi:10.1038/sj.bjp.0707659
41. Divakaran V, Adrogue J, Ishiyama M, Entman ML, Haudek S, Sivasubramanian N, Mann DL (2009) Adaptive and maladaptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail 2:633–642. doi:10.1161/CIRCHEARTFAILURE.108.823070
42. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350. doi:10.1161/01.RES.0000202804.84885.d0
43. Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, Maier L, Poller W, Blankenberg S, Schultheiss HP, Tschope C, Westermann D (2014) Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol 109:428. doi:10.1007/s00395-014-0428-7
44. Hantouche CM, Bitar KM, Nemer GM, Obeid MY, Kadi LN, Der-Boghossian AH, Bikhazi AB (2010) Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts. Can J Physiol Pharmacol 88:54–63. doi:10.1139/Y09-095
45. Mells JE, Fu PP, Sharma S, Olson DE, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA (2011) GLP-1 analogue, liraglutide ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet. Am J Physiol Gastrointest Liver Physiol 302:G225–G235. doi:10.1152/ajpgi.00274.2011
46. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y (2010) The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 298:H1454–H1465. doi:10.1152/ajpheart.00867.2009
47. Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693–700. doi:10.1016/j.jacc.2005.09.050
48. Sonne DP, Engstrom T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243–249. doi:10.1016/j.regpep.2007.10.001
49. Kain V, Prabhu S, Halade G (2014) Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109:444. doi:10.1007/s00395-014-0444-7
50. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R (2009) IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104:e9–e18. doi:10.1161/CIRCRESAHA.108.188243
51. Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:255–278. doi:10.1016/j.pharmthera.2009.05.002
52. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H (2010) inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030–1037. doi:10.2337/db09-1694
53. Troidl C, Mollmann H, Nef H, Masseli F, Voss S, Szardien S, Willmer M, Rolf A, Rixe J, Troidl K, Kostin S, Hamm C, Elsässer A (2009) Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 13:3485–3496. doi:10.1111/j.1582-4934.2009.00707.x
54. Wende AR, O’Neill BT, Bugger H, Riehle C, Tuinei J, Buchanan J, Tsushima K, Wang L, Caro P, Guo A, Sloan C, Kim BJ, Wang X, Pereira RO, McCrory MA, Nye BG, Benavides GA, Darley-Usmar VM, Shioi T, Weimer BC, Abel ED (2015) Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol Cell Biol 35:831–846. doi:10.1128/MCB.01109-14
55. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJ, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM (2004) Extracellular signal regulated kinase and SMAD signalling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 82:678–687. doi:10.1007/s00109-004-0579-3
56. Takuwa N, Ohkura SI, Takashima SI, Ohtani K, Okamoto Y, Tanaka T, Hirano K, Usui S, Wang F, Du W, Yoshioka K, Banno Y, Sasaki M, Ichi I, Okamura M, Sugimoto N, Mizugishi K, Nakanuma Y, Ishii I, Takamura M, Kaneko S, Kojo S, Satouchi K, Mitumori K, Chun J, Takuwa Y (2010) S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 85:484–493. doi:10.1093/cvr/cvp312
57. Li L, Okada H, Takemura G, Ki Kosai, Kanamori H, Esaki M, Takahashi T, Goto K, Tsujimoto A, Maruyama R, Kawamura I, Kawaguchi T, Takeyama T, Fujiwara T, Fujiwara H, Minatoguchi S (2009) Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. Am J Physiol Heart Circ Physiol 297:H1504–H1513. doi:10.1152/ajpheart.00194.2009
58. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6:556–563. doi:10.1038/75037
59. Hofmann U, Knorr S, Vogel B, Weirather J, Frey A, Ertl G, Frantz S (2014) Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail 7:822–830. doi:10.1161/CIRCHEARTFAILURE.113.001020
60. Ong SG, Lee WH, Huang M, Dey D, Kodo K, Sanchez-Freire V, Gold JD, Wu JC (2014) Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation 130:S60–S69. doi:10.1161/CIRCULATIONAHA.113.007917
61. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326. doi:10.1056/NEJMoa1307684
62. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after Acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335. doi:10.1056/NEJMoa1305889